73results about "Osteogenic factor" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of BMP9 as an intervention target in preparation of a medicine for treating diabetic nephropathy. More specifically, the invention provides application of a BMP9 accelerant in preparation of a medicine for preventing and / or treating diabetic nephropathy. The BMP9 accelerant is a substance shown in the following (i) or (ii): (i) a substance for increasing the content of BMP9 in a subject; (ii) a substance that increases BMP9 activity in a subject. According to the invention, a DKD mouse model is constructed, and liver RNA-seq sequencing is carried out, such that a differential expression gene BMP9 exists between a normal mouse and a DKD mouse. It is found that BMP9 can be used as a new target for prevention and treatment of DKD and has important theoretical significance and potential clinical application value.

The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.

To provide a bone morphogenetic protein-9 (BMP-9) variant in which heterotopic ossification side effect is alleviated, and a fusion thereof.SOLUTION: Provided are a bone morphogenetic protein-9 (BMP-9) variant expressed by a specific amino acid sequence, BMP-9 variant-Fc fusion protein in which an Fc fragment of immunoglobulin is connected to the BMP-9 variant, and a pharmaceutical composition for treating cardiopulmonary disease which contains the BMP-9 variant or the BMP-9 variant-Fc fusion protein as an active ingredient. The cardiopulmonary disease is one or more kinds selected from the group consisting of cardiac infarction, hypertension, pulmonary hypertension, myocardial fibrosis, and pulmonary fibrosis.SELECTED DRAWING: Figure 4b

The invention relates to an mRNA (messenger Ribonucleic Acid) medicine and application thereof in treating pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding peptides comprising a BMP9 active molecule and / or an ACTRIIA ligand trapping agent, lipid nanoparticles comprising said polynucleotides, and therapeutic uses thereof.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.

In one aspect, the invention relates to synthetic molecules, compositions and pharmaceutical compositions, which are useful for delivering a bioactive moiety to a site of injury. Also disclosed are methods of treating a tendon injury, methods of treating a fracture, methods of treating a bone stress injury, methods of enhancing incorporation of allograft tissues, methods of promoting repair or regeneration of enthesis tissue during or after an orthopedic surgical procedure, and method of treating osteoporosis, osteoarthritis and / or cartilage defects using the disclosed molecules, compositions and pharmaceutical compositions.

The application provides a method for constructing a Bmp4 gene knock-in mouse model, and the method comprises the following steps: obtaining sgRNA12 shown in SEQ ID NO. 3; mixing the sgRNA12, Cas9 mRNA and a targeting vector shown in SEQ ID NO. 1, and then microinjecting into a mouse zygote to obtain F0 generation mice; selecting F0 generation positive mice in genotype identification results of the F0 generation mice, and mating the F0 generation positive mice with wild type mice to obtain F1 generation mice with stable genotypes; and screening gene targeting mice with correct recombination, and mating the gene targeting mice with retinal specific knock-out tool mice Six3-Cre to obtain Bmp4 gene knock-in model mice. The method has high gene editing efficiency, and the transgenic mouse can highly express human Bmp4 protein.

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45Å (Angstroms) or less.

A polypeptide or a modifier thereof having an effect of promoting bone formation; can be used for preventing and / or treating bone diseases.

The instant disclosure relates to methods for converting mammalian definitive endoderm (DE) cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the disclosure relates to formation of esophageal tissue and / or organoids formed from differentiated definitive endoderm.

It is an object of the present invention to provide a novel means for treating a hair cycle-related disease or symptom (hair cycle-related disease etc. Provided is a miR-520d-p polynucleotide or a polynucleotide encoding thereof or a compound for upregulating miR-520d-5p for use in reverting a mutation in a hair cycle-related gene to wild type in a cell, wherein the polynucleotide comprises: (a1) a nucleotide sequence set forth in SEQ ID NO:1: or (a2) a nucleotide sequence having 1 to 3 nucleotide deletions, substitutions, insertions or additions in the nucleotide sequence set forth in SEQ ID NO:1. SEQ ID NO:1 (single-stranded miRNA sequence) 5′-CUACAAAGGGAAGCCCUUUC-3

To provide human colonic organoids in vitro, usable for determining the efficacy and / or toxicity of potential therapeutics for a disease selected from the group consisting of colitis, colon cancer, polyposis syndrome and / or irritable bowel syndrome.SOLUTION: The disclosure provides a human colonic organoid (HCO), where the human colonic organoid comprises epithelium and mesenchyme and expresses SATB2, MUC2 and / or MUC5B.SELECTED DRAWING: Figure 1A

A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i) to iii): i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-β (TGF-β) inhibitor.

A process is provided for treating demineralized bone (DB) comprising incubating the DB with a solution of a chaotropic agent at a temperature in the range of about 12°C to about 30°C to increase the release of a bone growth factor followed by selectively removing the chaotropic agent while retaining the released growth factor and the DB. A product prepared by the process is also provided as is the use of said product to promote bone formation or bone fusion in a subject in need thereof.

Aspects of the present disclosure relate generally to chimeric proteins and pharmaceutical compositions comprising such chimeric proteins, and methods for using such chimeric proteins for treating kidney diseases. Aspects of the disclosure relate to a chimeric protein comprising a targeting domain comprising a scFv having a binding specificity to a cell surface protein of a kidney tissue, and an activator domain comprising a growth factor.

As a technique for obtaining a neural retinal sheet with improved uniformity of the thickness of the neural retinal progenitor cell layer, provided is a method of producing a tissue comprising neural retinal progenitor cells in a region A of a culture substrate comprising a region A provided with a surface having cell adhesiveness and a region B provided around the region A and with a surface having less cell adhesiveness than the region A, by culturing pluripotent stem cells in an adhesive state in the region A in the presence of a differentiation-inducing factor, wherein the surface of the region A is coated with a cell-adhesive material, and has a contact angle within a predetermined range before being coated with the cell-adhesive material.

The invention relates to the technical field of biological medicine, in particular to an extra CCAAT box in a low-heart-rate long-life mammal GDF11 promoter capable of reducing the resting heart rate and promoting longevity. According to the invention, a regulatory element capable of co-evolution with prolonged life and low heart rate is found by using bioinformatics and gene editing animals. On the basis, the invention provides a functional control region in a GDF11 gene promoter region, the functional region comprises two CCAAT boxes, and the positions of the two CCAAT boxes are respectively located at the 194th-198th basic groups of the GDF11 gene promoter. The functional control region in the GDF11 gene promoter region provided by the invention can promote the longevity, low heart rate and senescence delaying of mammals, can also be used for constructing animal models with reduced resting heart rate and / or senescence delaying, and provides a promising way for research and development of treatment means for senescence and heart rate related diseases.

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.

The present disclosure relates to the nucleic acids encoding a proprotein and at least one enzyme for processing the proprotein into a mature protein. In particular, the present disclosure relates to nucleic acids encoding an inactive proprotein and at least one enzyme for cleavage of the proprotein to produce an active protein.

The present invention relates to mRNA drugs and their use in the treatment of pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding a peptide comprising a BMP9 active molecule and / or an ACTRIIA ligand trap, lipid nanoparticles comprising said polynucleotides and their therapeutic use.

Provided are dual-affinity fusion proteins including an affibody domain specific for a therapeutic protein, and including a localization domain specific for a structural bone component. The therapeutic protein can include bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), or glial derived neurotrophic factor (GDNF). Also provided are compositions that include the dual-affinity fusion proteins, affibodies and the corresponding therapeutic proteins, and / or a medical material used to treat a wound, or a bone or cartilage injury or disease. Also provided are methods of using the compositions, for example to treat bone injuries, bone diseases, cartilage injuries, cartilage diseases, and wounds. In some examples, the composition includes at least two different dual-affinity fusion proteins specific for the same therapeutic protein, but have different disassociation constants (KD).

The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and / or dopaminergic neuronal cells. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.